Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). — Stella

Home/Multiple Sclerosis, Secondary Progressive/Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

View on ClinicalTrials.gov

Recruiting

Back to Multiple Sclerosis, Secondary Progressive trials

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Poland

Institute of Psychiatry and Neurology, Warsaw, Masovian Voivodeship

Key details

Phase

Safety & dosing / Large-scale testing

Sponsor

Institute of Psychiatry and Neurology, Warsaw

Collaborators

Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Mossakowski Medical Research Centre Polish Academy of Sciences

Enrollment target

~188 participants

Started

October 2022

Primary completion

June 2027

Age range

30 Years – 65 Years

Last updated July 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.